The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

[^key-5527cda7c6b878fff7e91c32dcec5bc3]: Words in reg. 203(4) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 157(c)(i)

[^key-7b7ed4a1f4096caecba589cdeeb03399]: Words in reg. 203(4) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 157(c)(ii)

[^key-2ed4119a5c0eb35597d0891f08d88216]: Words in reg. 204(2) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 158(a)

[^key-c6fc64a3df3fd748e0703b839a68004e]: Words in reg. 204(3) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 158(b)

[^key-3f4fee243ff88c24f6f75398f3e4e404]: Word in reg. 204(4) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 158(c)(i)

[^key-b3ad1d850cedf6c7c8ad2ecc9c1334e5]: Words in reg. 204(4) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 158(c)(ii)

[^key-90b4eb4c991f3b7291b73c0ee2f6febb]: Word in reg. 204(5)(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 158(d)(i)

[^key-1752c2d70c736a83fedbeb7daa6cb495]: Words in reg. 204(5)(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 158(d)(ii)

[^key-b848d069a1f9e5b38090a74857761d40]: Words in reg. 204(6) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 158(e)

[^key-f9af1b289857e3fdb7a1830a4fa5c2fe]: Reg. 205 omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 159

[^key-5f030121ee60870dbb8e38a3e39b9fc6]: Words in reg. 206 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 160

[^key-3835d7a5884b53e57d062a3ac65ef7ce]: Reg. 207(1A) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 161(a)

[^key-a85b196c9fecd255523c8703dfcf5197]: Reg. 207(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 161(b)

[^key-d965e8ca15d81ca1b9ffc7102ed5e7fc]: Reg. 208(1A) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 163(a)

[^key-7000dadd0ae3abe8f845b0e03d7170e2]: Reg. 208(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 163(b)

[^key-87c9032ea9dcfdbdefc9f9434f4a886e]: Reg. 208(2A) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 163(c)

[^key-8ce87379ded6d8d407a042b6dc9c4a97]: Words in reg. 209 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 165

[^key-2f62239202d6893fca6298d81d88a2db]: Reg. 211 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 167

[^key-04c8ebbb7b5f2f4ca5d8541c5aad7092]: Word in reg. 212 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 168(a)

[^key-f8d275f5d421a284970f38f2b5709a22]: Words in reg. 212(a) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 168(b)(i)

[^key-019065cb863b77b6da671f9d03ccbe81]: Words in reg. 212(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 168(b)(ii)

[^key-d44f0c1dd6f566106cac1ff0f184e274]: Reg. 212(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 168(c)

[^key-878641762ab5e4f53e2ed857deca22d5]: Reg. 213(b)(c) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 169

[^key-311448e6e2dbeb2db9145bbf7ab5a1c5]: Reg. 214 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 171

[^key-e1cac40798fdbecec582a56f1af9d3b3]: Reg. 215 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 173

[^key-bf808d1f9b2af0893e8acfaea4521ffe]: Reg. 216 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 175

[^key-c4f02ae4b3ce39f0b231ac7c6d0e0677]: Words in reg. 217 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 176

[^key-b0962ec3e8ca1c19ff85559f3df4eb08]: Reg. 218(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 178

[^key-126abff68f78b01fc3a98f5cc2402147]: Reg. 219 omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 179

[^key-8d00d047550aa985f731c822df25a2eb]: Reg. 221(2)(b) substituted for reg. 221(2)(b)(c) (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 180(a)

[^key-c93877db17ff348e1c453832d1e256ba]: Reg. 221(3) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 180(b)

[^key-7eb410aa9d5fd8d935169e67556fa101]: Reg. 221(4) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 180(c)

[^key-3994fea9b411e055c83bb0df450872e2]: Reg. 221(5) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 180(c)

[^key-d341c41e978df774d9276a5ec5f9e392]: Reg. 222(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 181(a)

[^key-63f2eec705d4551ad16341b409ee4778]: Reg. 222(3) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 181(b)

[^key-8adf85a39e58734072ae84c658987500]: Words in reg. 223 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 182

[^key-0857e006066cb7e0327d883dae3b2d38]: Reg. 224 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 184

[^key-5e78e9305f85c76ecee7aea827113116]: Words in reg. 225 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 185

[^key-dbc6030782d9efe6c9dea81fdd3c9959]: Reg. 226 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 186

[^key-b34831c4c071541bf6d83c0ee133c048]: Words in reg. 227(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 187(a)

[^key-5fad172bf71f8a4f9aff51d7cabf1a02]: Words in reg. 227(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 187(b)

[^key-dfc9f43400b121b95ef394584218074c]: Sch. 1 para. 1(aa) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(b)

[^key-28d345b9aef06551dec1a6846b92e491]: Words in Sch. 1 para. 2 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(c)(i)(aa)

[^key-2716bfef33b37cfa15410ae572b26ac9]: Words in Sch. 1 para. 2 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(c)(i)(bb)

[^key-1ac432924efd0b63b6ddcdd0c38f772d]: Words in Sch. 1 para. 2 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(c)(ii)(aa)

[^key-5c246ad423fccdd087198076d5bdfc2e]: Word in Sch. 1 para. 2 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(c)(ii)(bb)

[^key-91d6fe281bfa5cd70f72dbfdffc8d816]: Sch. 1 para. 3(2)-(4) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(d)

[^key-c97c0b20038dda7126a96f632a0f2a19]: Words in Sch. 1 para. 4 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(e)

[^key-8e3d198892599ad17b101ed596c85074]: Sch. 1 para. 6(ai) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(f)(i)

[^key-51596c424598a455c7e3676b4399331c]: Words in Sch. 1 para. 6(a)(iv) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(f)(ii)

[^key-0e30c9083c62481989eb91254ec32bc9]: Sch. 1 para. 7(8A) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(vi)

[^key-273ff2c171e5313c86fbac94a425102d]: Sch. 1 para. 7(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(i)

[^key-2f1f9c7e874a9bc4041c552a9ef0576f]: Words in Sch. 1 para. 7(3)(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(ii)(aa)

[^key-71ddd39244580baf93bfe316c520c846]: Words in Sch. 1 para. 7(3)(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(ii)(bb)

[^key-800d83c6e05a33dfbd7001351fa69c9c]: Words in Sch. 1 para. 7(3)(c) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(ii)(cc)

[^key-00149a9c17ef6f381ca64f7abf225559]: Words in Sch. 1 para. 7(4)(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(iii)(aa)

[^key-c5e55a429dc6f27a6c8a1f770acfc17d]: Words in Sch. 1 para. 7(4)(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(iii)(bb)

[^key-020b4aaf8ed392cf138da8251c979666]: Words in Sch. 1 para. 7(4)(c) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(iii)(cc)

[^key-fa073468b379e4bbdfbcbb0a896483be]: Sch. 1 para. 7(5) Table substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(iv)

[^key-93c354dd52255f283b602e0b6f7f9b3d]: Words in Sch. 1 para. 7(6) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(v)(aa)

[^key-8258018e2b061a55736698cb356c9c01]: Words in Sch. 1 para. 7(6) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(v)(bb)

[^key-968931078a2e45cc8777fa01275c3891]: Sch. 1 para. 7(9) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(vii)

[^key-4dd94647d9bd2489ad03b71cd8a68f75]: Words in Sch. 1 para. 7(12) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(viii)(aa)

[^key-d205414feb4cb45b24a022bfb9a2458f]: Words in Sch. 1 para. 7(12) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(viii)(bb)

[^key-c0420a24f153312a7fc969486510b6b2]: Words in Sch. 1 para. 7(13) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(ix)(aa)

[^key-f3cb389ce632a3a8ac8b27a6835c317e]: Words in Sch. 1 para. 7(13) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(ix)(bb)

[^key-5a15e1d834bf61576e606b836f9d7005]: Words in Sch. 8 para. 4 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(a)(i)

[^key-6f012dd56981b3f067d60f35fd3e7444]: Words in Sch. 8 para. 4 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(a)(ii)

[^key-535c0e619935ca3f575605e18dcf8207]: Sch. 8 para. 7 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(c)

[^key-e5d5e655e8b35ff20d3cf58e6fe4f32a]: Words in Sch. 8 para. 8 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(b)(i)

[^key-1a64f0ca3b3ec8a3cfdc41b88216eb25]: Words in Sch. 8 para. 8 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(b)(ii)

[^key-1428517187a2b7f6ed51201130b7d00e]: Sch. 8 para. 16(3) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(ii)

[^key-9d59c48600ae960e952859330ff209cf]: Sch. 8 para. 16(4)(a)(i) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(iii)

[^key-3c9212a88f5f8d5b6d46fba721f65d6e]: Sch. 8 para. 16(4)(a)(ii) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(iv)

[^key-d80fc6fe37f15fd51ef6a148e663e6dc]: Sch. 8 para. 16(4)(b) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(v)

[^key-b467319f5f3fb1322a2597b768f1a443]: Sch. 8 para. 16(5) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(vi)

[^key-2e1cdcacc59ebd85bdacff3bde8c4a56]: Sch. 8 para. 16(6) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(vii)

[^key-85b8c2cb48a0ea98e999680a00f3c234]: Sch. 8 para. 16(2)(a)-(d) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(i)

[^key-5dd8152020d7d3270b580168d6bcd631]: Sch. 9 para. 1(jj) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 195

[^M_I_23e33a84-7c47-471a-eeab-6baccd24dca1]: Reg. 56 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_cf5d7bb4-cbc2-40a6-b09e-cfa60a8de70b]: Reg. 57 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_9bb60729-126e-4ab5-bc90-521d3d5d74b8]: Reg. 58 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_acde96ff-04df-4150-996d-ec5407389936]: Reg. 60 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_d1857864-fa74-4bba-f9ff-aebdc40608ad]: Reg. 66 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_e2103c0e-5867-4227-9e8a-139ff66d1035]: Reg. 69 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_06066963-dd5c-406c-c833-08add28d3113]: Reg. 81 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_55a3b3b3-fa37-405f-f099-d3b17258571b]: Reg. 84 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_971b860d-3d75-42c0-9c4b-c6654e16c340]: Reg. 88 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_330cbe6c-1c52-4b19-8f5a-b27ef18735ae]: Reg. 91 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_6430591b-820a-4eca-e7ac-b39fa72800fe]: Reg. 92 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_d93b0822-473f-4fc4-87ab-8516d9cf39f7]: Reg. 100 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_2f0907a2-8e7d-4a23-f44a-868e4278cf13]: Reg. 107 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_f6e396a4-fa0a-4867-a3d0-82577826ac47]: Reg. 113 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_6fbc7ee7-8169-422c-a96d-e3ef1606ffe6]: Reg. 114 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-f8a89d960686da5802102e895a26a756]: Reg. 62(4) substituted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 45(b)

[^M_I_866119db-e9d6-4a5c-8198-82552bd1674d]: Reg. 127 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_78228c6a-f93a-4ff1-c544-47c1e08a9f8f]: Reg. 129 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_565e0815-aab1-42c4-a0b5-1d38983f3025]: Reg. 131 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_23fe2b4c-8159-4e7b-ed0a-c076257877be]: Reg. 135 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_efe4236a-66c8-43c4-cf8a-d414ef89d236]: Reg. 141 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_1f492c40-c993-4779-8d22-5fb7cdf22014]: Reg. 145 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_5253bf14-41b3-48ed-a470-dda7e2e4f166]: Reg. 150 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_8b38e121-4ae7-44b2-8a59-002970b72990]: Reg. 162 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_c95e523f-c1bc-4a8d-965f-1dd930deb45e]: Reg. 177 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_e863559c-f5ec-4daf-f9bf-02c5ee28a2d7]: Reg. 187 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_cf8dbaaf-fa2d-4cc4-a261-da09001264f4]: Reg. 188 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_c625fbe1-9783-4654-8041-5a01c217f4dc]: Reg. 189 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_db4c99ac-96a5-46a4-8fbe-20ab285185cb]: Reg. 190 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_fd6ed0a5-9b8b-463a-e5c3-9d43ebec5164]: Reg. 191 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_2e1d4601-3df8-48e2-aede-1b33f3907648]: Reg. 192 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_30fce088-b0a9-47ae-eeac-07cba0f9eda3]: Reg. 197 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_fe725cba-182a-4360-e49e-1124ef90a382]: Reg. 214 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_86803d27-6c34-4f03-a45f-556799e68e78]: Reg. 215 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_6e5cd898-8e3e-48ea-ecc7-ce2e64a45986]: Reg. 216 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_97fc1d16-d95e-4135-e08a-25bdf5546e45]: Reg. 224 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_bbc8e6bd-caf0-4daa-e0d1-a9c67161e19e]: Reg. 226 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_44ffbdf1-0b67-4064-d934-b6b7ee6674ab]: Sch. 8 para. 7 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_7a3e67f8-56ec-437e-e0fe-f4e917aaa252]: Reg. 19A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_5d22e12d-9299-4749-f2c8-56db8afa762e]: Reg. 51A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_52a5ecd7-7fd8-47d2-87c2-5c331623fc30]: Reg. 76A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_14f0170f-a781-4cd8-83e6-e2e7746ee2fb]: Reg. 101A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_43bb0cdf-a452-45d2-b5a2-d5df8c6614a1]: Reg. 118A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_91de5844-ef39-4d39-ebcf-2ab5124fa7ca]: Reg. 135ZA in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_813a8d24-56d7-4104-9336-897561e42ddd]: Reg. 139A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_abcd60ee-3e87-477b-8fee-9cbb4f4b7cdb]: Reg. 156ZA in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_f2d1b4ce-1aa2-494e-f297-bc901578ddfd]: Reg. 194A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_9453d031-a354-4304-e02d-38c3a51bcd4f]: Reg. 196A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_22bd05d3-afdd-4d07-ae32-0138d493fc23]: Reg. 196 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_76bc4d53-834b-4105-df8b-e06892402d77]: Reg. 90 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_b14fd4c4-3877-4e65-db19-81cf7981c01f]: Reg. 90A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_ae1a7d05-1931-489f-8503-e71b5c5dbcd1]: Reg. 90B in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_87f76c4a-a1d4-4263-ae57-8fd7260a7b8a]: Reg. 132 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_3f72faf5-51f6-4268-e492-34095d32e530]: Reg. 132A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_3742a371-26e7-414d-b4b3-618586d47475]: Reg. 199 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_49434a22-3d9e-421a-fe48-29b4ecc0754a]: Reg. 199A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_dfd785b7-40a6-47e4-e5fb-0d00bcbbf0d0]: Reg. 207A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_4f6b8147-4400-470d-9eed-725865de8203]: Reg. 208A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_e105635a-cb9d-479a-a030-e5f83006217e]: Reg. 209A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_bfa08717-ee69-4577-af78-033216e2594a]: Reg. 213A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_5984aaa4-76d6-4d98-9799-0c00e9cce6de]: Reg. 214A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_ae25c194-20a7-4f86-edec-7eef90617086]: Reg. 215A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_7a2068ff-49f8-4c4c-80fc-9ede0f7ab590]: Reg. 217A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_85eabc59-e010-46e4-a04e-23a7b1d8cc23]: Reg. 217B in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_f845981a-78f1-48f6-c5b4-2d3c25e60530]: Reg. 217C in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_dd0437c5-f36d-471d-ce86-8630a2c756a8]: Reg. 217D in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_c87da6a4-7d55-4950-d833-e2bd4bc8e0e4]: Reg. 224ZA in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_a4989715-db71-41eb-bd15-354104a4d6e3]: Reg. 224ZB in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_5c498f54-8b88-4786-def8-6fdb33bf5739]: Reg. 224ZC in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_4511cbb6-ec0c-49fa-e550-f568c865d4da]: Reg. 224ZD in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_a1ed52ca-3348-4d49-fe78-292eaba79d6f]: Sch. 1 para. 1ZA in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_1fa70f84-dd80-45a7-e5d9-55a42c0b2729]: Sch. 1 para. 8A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_9c7f0136-6e2a-40cf-e179-b90354c038e3]: Sch. 2A para. 1 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_86672a58-9052-4500-943f-9cb1735712ee]: Reg. 6 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_bfd7d6e5-60e3-43c3-f92f-bb99bd70d747]: Reg. 21 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_013f0b6d-fadf-41a7-f84b-6fda83e66816]: Reg. 31 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^M_I_31893983-9eb8-4eac-c574-739652e5634e]: Reg. 34 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

[^key-7ad11b733c108e4be9b3ed7ad5560cc8]: Reg. 5(3)(b) omitted (3.8.2021) by virtue of The Human Medicines (Amendment) (EU Exit) Regulations 2021 (S.I. 2021/834), regs. 1(2), 3